Atrium Therapeutics, a precision cardiology biotech company, reported its Q1 2026 financial results and corporate progress following its spin-off and Nasdaq listing. The company earned a $15 million milestone payment from Bristol Myers Squibb after delivering a development candidate targeting heart disease. Atrium is advancing its lead RNA therapeutic programs ATR 1072 and ATR 1086, with plans to submit IND applications and start clinical trials by late 2026 and 2027. With $267.8 million cash on hand, Atrium aims to pioneer RNA treatments for rare genetic cardiomyopathies with limited options today.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
